$AMLN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in AMYLIN PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in AMYLIN PHARMACEUTICALS INC. Get notifications about new insider transactions in AMYLIN PHARMACEUTICALS INC for free.
Page: < prev 1 ... 2 3 4 5 6 7 8 9 ... 18 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Sell | S | 15.03 | 2,500 | 37,566 | 155,136 | 157.6 K to 155.1 K (-1.59 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Buy | M | 5.73 | 2,500 | 14,325 | 157,636 | 155.1 K to 157.6 K (+1.61 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Sell | S | 15.02 | 5,000 | 75,087 | 155,136 | 160.1 K to 155.1 K (-3.12 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Buy | M | 11.13 | 5,000 | 55,625 | 160,136 | 155.1 K to 160.1 K (+3.22 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Grant | A | 0.00 | 15,000 | 0 | 155,136 | 140.1 K to 155.1 K (+10.70 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | A | 15.03 | 62,467 | 938,879 | 62,467 | |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | A | 15.03 | 7,533 | 113,221 | 7,533 | |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Grant | A | 0.00 | 1,630 | 0 | 6,445 | 4.8 K to 6.4 K (+33.85 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Grant | A | 0.00 | 15,000 | 0 | 21,666 | 6.7 K to 21.7 K (+225.02 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | A | 15.03 | 70,843 | 1,064,770 | 70,843 | |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | A | 15.03 | 9,157 | 137,630 | 9,157 | |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Grant | A | 0.00 | 1,630 | 0 | 6,445 | 4.8 K to 6.4 K (+33.85 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Grant | A | 0.00 | 15,000 | 0 | 41,457 | 26.5 K to 41.5 K (+56.70 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | A | 15.03 | 243,347 | 3,657,505 | 243,347 | |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | A | 15.03 | 6,653 | 99,995 | 6,653 | |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Grant | A | 0.00 | 1,630 | 0 | 6,445 | 4.8 K to 6.4 K (+33.85 %) |
| Mar 03 2011 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Grant | A | 0.00 | 25,000 | 0 | 32,178 | 7.2 K to 32.2 K (+348.29 %) |
| Feb 15 2011 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Option Exercise | X | 0.00 | 2,251 | 0 | 8,536 | |
| Feb 15 2011 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Sell | S | 14.94 | 671 | 10,025 | 1,580 | 2.3 K to 1.6 K (-29.81 %) |
| Feb 15 2011 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Buy | X | 14.94 | 2,251 | 33,630 | 2,251 | 0 to 2.3 K |
| Feb 01 2011 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Option Exercise | M | 11.13 | 2,500 | 27,813 | 5,350 | |
| Feb 01 2011 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Sell | S | 16.16 | 2,500 | 40,409 | 151,639 | 154.1 K to 151.6 K (-1.62 %) |
| Feb 01 2011 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Buy | M | 11.13 | 2,500 | 27,813 | 154,139 | 151.6 K to 154.1 K (+1.65 %) |
| Jan 18 2011 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Option Exercise | M | 11.13 | 2,500 | 27,813 | 7,850 | |
| Jan 18 2011 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Sell | S | 15.00 | 2,500 | 37,500 | 151,639 | 154.1 K to 151.6 K (-1.62 %) |
| Jan 18 2011 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Buy | M | 11.13 | 2,500 | 27,813 | 154,139 | 151.6 K to 154.1 K (+1.65 %) |
| Jan 11 2011 | AMLN | AMYLIN PHARMACEUTI ... | DENNER ALEXANDER J | Director | Option Exercise | A | 0.00 | 1,104 | 0 | 1,104 | |
| Jan 07 2011 | AMLN | AMYLIN PHARMACEUTI ... | SULLIVAN JOSEPH P | Director | Option Exercise | A | 0.00 | 1,147 | 0 | 18,070 | |
| Jan 07 2011 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Option Exercise | A | 0.00 | 430 | 0 | 10,786 | |
| Jan 07 2011 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Option Exercise | A | 0.00 | 1,274 | 0 | 14,595 | |
| Nov 22 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | M | 11.13 | 18,589 | 206,803 | 0 | |
| Nov 22 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | M | 11.13 | 6,411 | 71,322 | 0 | |
| Nov 22 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Buy | M | 11.13 | 18,589 | 206,803 | 74,573 | 56 K to 74.6 K (+33.20 %) |
| Nov 22 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Buy | M | 11.13 | 6,411 | 71,322 | 55,984 | 49.6 K to 56 K (+12.93 %) |
| Nov 19 2010 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | S | 13.42 | 1,314 | 17,634 | 3,357 | 4.7 K to 3.4 K (-28.13 %) |
| Oct 05 2010 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Option Exercise | A | 0.00 | 425 | 0 | 10,356 | |
| Oct 05 2010 | AMLN | AMYLIN PHARMACEUTI ... | SULLIVAN JOSEPH P | Director | Option Exercise | A | 0.00 | 809 | 0 | 16,924 | |
| Oct 05 2010 | AMLN | AMYLIN PHARMACEUTI ... | CLARK PAUL N | Director | Option Exercise | A | 0.00 | 1,169 | 0 | 5,573 | |
| Oct 05 2010 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Option Exercise | A | 0.00 | 899 | 0 | 13,321 | |
| Jul 07 2010 | AMLN | AMYLIN PHARMACEUTI ... | SULLIVAN JOSEPH P | Director | Option Exercise | A | 0.00 | 918 | 0 | 16,115 | |
| Jul 07 2010 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Option Exercise | A | 0.00 | 482 | 0 | 9,932 | |
| Jul 07 2010 | AMLN | AMYLIN PHARMACEUTI ... | CLARK PAUL N | Director | Option Exercise | A | 0.00 | 782 | 0 | 4,405 | |
| Jul 07 2010 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Option Exercise | A | 0.00 | 1,020 | 0 | 12,422 | |
| Jun 01 2010 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | M | 10.25 | 10,000 | 102,500 | 0 | |
| Jun 01 2010 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Payment of Exercise | F | 16.52 | 6,204 | 102,490 | 73,796 | 80 K to 73.8 K (-7.75 %) |
| Jun 01 2010 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Buy | M | 10.25 | 10,000 | 102,500 | 80,000 | 70 K to 80 K (+14.29 %) |
| May 03 2010 | AMLN | AMYLIN PHARMACEUTI ... | DENNER ALEXANDER J | Director | Option Exercise | A | 21.52 | 20,000 | 430,400 | 20,000 | |
| Apr 30 2010 | AMLN | AMYLIN PHARMACEUTI ... | SULLIVAN JOSEPH P | Director | Option Exercise | A | 21.52 | 20,000 | 430,400 | 20,000 | |
| Apr 30 2010 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | A | 21.52 | 20,000 | 430,400 | 20,000 | |
| Apr 30 2010 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Option Exercise | A | 21.52 | 20,000 | 430,400 | 20,000 | |
| Apr 30 2010 | AMLN | AMYLIN PHARMACEUTI ... | EASTHAM KARIN | Director | Option Exercise | A | 21.52 | 20,000 | 430,400 | 20,000 | |
| Apr 30 2010 | AMLN | AMYLIN PHARMACEUTI ... | Costa Paulo F | Director | Option Exercise | A | 21.52 | 20,000 | 430,400 | 20,000 | |
| Apr 30 2010 | AMLN | AMYLIN PHARMACEUTI ... | CLARK PAUL N | Director | Option Exercise | A | 21.52 | 20,000 | 430,400 | 20,000 | |
| Apr 30 2010 | AMLN | AMYLIN PHARMACEUTI ... | BEHRENS M KATHLEEN | Director | Option Exercise | A | 21.52 | 20,000 | 430,400 | 20,000 | |
| Apr 30 2010 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Option Exercise | A | 21.52 | 20,000 | 430,400 | 20,000 | |
| Apr 30 2010 | AMLN | AMYLIN PHARMACEUTI ... | ADAMS ADRIAN | Director | Option Exercise | A | 21.52 | 20,000 | 430,400 | 20,000 | |
| Apr 07 2010 | AMLN | AMYLIN PHARMACEUTI ... | SULLIVAN JOSEPH P | Director | Option Exercise | A | 0.00 | 734 | 0 | 15,196 | |
| Apr 07 2010 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Option Exercise | A | 0.00 | 386 | 0 | 9,450 | |
| Apr 07 2010 | AMLN | AMYLIN PHARMACEUTI ... | CLARK PAUL N | Director | Option Exercise | A | 0.00 | 626 | 0 | 3,623 | |
| Apr 07 2010 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Option Exercise | A | 0.00 | 816 | 0 | 11,402 | |
| Apr 07 2010 | AMLN | AMYLIN PHARMACEUTI ... | ALTMAN STEVEN R | Director | Option Exercise | A | 0.00 | 626 | 0 | 9,899 | |
| Apr 06 2010 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | M | 13.25 | 638 | 8,454 | 0 | |
| Apr 06 2010 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Buy | M | 13.25 | 638 | 8,454 | 28,138 | 27.5 K to 28.1 K (+2.32 %) |
| Mar 26 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | M | 9.63 | 1,567 | 15,082 | 0 | |
| Mar 26 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | M | 9.63 | 1,666 | 16,035 | 1,567 | |
| Mar 26 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | M | 9.63 | 1,667 | 16,045 | 3,233 | |
| Mar 26 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | M | 9.63 | 100 | 963 | 0 | |
| Mar 26 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Buy | M | 9.63 | 1,567 | 15,082 | 49,573 | 48 K to 49.6 K (+3.26 %) |
| Mar 26 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Buy | M | 9.63 | 1,666 | 16,035 | 48,006 | 46.3 K to 48 K (+3.60 %) |
| Mar 26 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Buy | M | 9.63 | 1,667 | 16,045 | 46,340 | 44.7 K to 46.3 K (+3.73 %) |
| Mar 26 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Buy | M | 9.63 | 100 | 963 | 44,673 | 44.6 K to 44.7 K (+0.22 %) |
| Feb 22 2010 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP Research & Dev ... | Option Exercise | M | 14.28 | 5,436 | 77,632 | 0 | |
| Feb 22 2010 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP Research & Dev ... | Option Exercise | M | 14.28 | 19,564 | 279,393 | 0 | |
| Feb 22 2010 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP Research & Dev ... | Payment of Exercise | F | 17.98 | 4,317 | 77,620 | 149,983 | 154.3 K to 150 K (-2.80 %) |
| Feb 22 2010 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP Research & Dev ... | Buy | M | 14.28 | 5,436 | 77,632 | 154,300 | 148.9 K to 154.3 K (+3.65 %) |
| Feb 22 2010 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP Research & Dev ... | Payment of Exercise | F | 17.98 | 15,539 | 279,391 | 148,864 | 164.4 K to 148.9 K (-9.45 %) |
| Feb 22 2010 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP Research & Dev ... | Buy | M | 14.28 | 19,564 | 279,393 | 164,403 | 144.8 K to 164.4 K (+13.51 %) |
| Feb 19 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | M | 14.28 | 47,606 | 679,861 | 0 | |
| Feb 19 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Payment of Exercise | F | 17.82 | 35,118 | 625,803 | 44,573 | 79.7 K to 44.6 K (-44.07 %) |
| Feb 19 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Buy | M | 14.28 | 44,573 | 636,547 | 79,691 | 35.1 K to 79.7 K (+126.92 %) |
| Feb 19 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Payment of Exercise | F | 17.82 | 3,033 | 54,048 | 16,524 | 19.6 K to 16.5 K (-15.51 %) |
| Feb 19 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Buy | M | 14.28 | 3,033 | 43,314 | 19,557 | 16.5 K to 19.6 K (+18.36 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP Governance Comp ... | Option Exercise | A | 18.01 | 12,919 | 232,671 | 12,919 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP Governance Comp ... | Option Exercise | A | 18.01 | 7,081 | 127,529 | 7,081 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP Governance Comp ... | Grant | A | 0.00 | 1,360 | 0 | 4,815 | 3.5 K to 4.8 K (+39.36 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP Governance Comp ... | Grant | A | 17.83 | 412 | 7,346 | 26,684 | 26.3 K to 26.7 K (+1.57 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP Chief Financia ... | Option Exercise | A | 18.01 | 44,243 | 796,816 | 44,243 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP Chief Financia ... | Option Exercise | A | 18.01 | 5,757 | 103,684 | 5,757 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP Chief Financia ... | Grant | A | 0.00 | 1,360 | 0 | 4,815 | 3.5 K to 4.8 K (+39.36 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP Chief Financia ... | Grant | A | 17.83 | 412 | 7,346 | 26,412 | 26 K to 26.4 K (+1.58 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP Research & Dev ... | Option Exercise | A | 18.01 | 53,356 | 960,942 | 53,356 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP Research & Dev ... | Option Exercise | A | 18.01 | 6,644 | 119,658 | 6,644 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP Research & Dev ... | Grant | A | 0.00 | 1,360 | 0 | 4,815 | 3.5 K to 4.8 K (+39.36 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP Research & Dev ... | Grant | A | 17.83 | 412 | 7,346 | 144,839 | 144.4 K to 144.8 K (+0.29 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | MARCHETTI ROGER | SVP Human Resource ... | Option Exercise | A | 18.01 | 53,669 | 966,579 | 53,669 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | MARCHETTI ROGER | SVP Human Resource ... | Option Exercise | A | 18.01 | 6,331 | 114,021 | 6,331 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | MARCHETTI ROGER | SVP Human Resource ... | Grant | A | 0.00 | 1,360 | 0 | 4,815 | 3.5 K to 4.8 K (+39.36 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | MARCHETTI ROGER | SVP Human Resource ... | Grant | A | 17.83 | 412 | 7,346 | 6,473 | 6.1 K to 6.5 K (+6.80 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Mihalik Vincent P | SVP Chief Commerci ... | Option Exercise | A | 18.01 | 48,968 | 881,914 | 48,968 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Mihalik Vincent P | SVP Chief Commerci ... | Option Exercise | A | 18.01 | 6,032 | 108,636 | 6,032 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Mihalik Vincent P | SVP Chief Commerci ... | Grant | A | 0.00 | 1,360 | 0 | 1,360 | 0 to 1.4 K |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Mihalik Vincent P | SVP Chief Commerci ... | Grant | A | 17.83 | 412 | 7,346 | 412 | 0 to 412 |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Lloyd Marcea Bland | SVP Gov Corp Affa ... | Option Exercise | A | 18.01 | 53,669 | 966,579 | 53,669 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Lloyd Marcea Bland | SVP Gov Corp Affa ... | Option Exercise | A | 18.01 | 6,331 | 114,021 | 6,331 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Lloyd Marcea Bland | SVP Gov Corp Affa ... | Grant | A | 0.00 | 1,360 | 0 | 4,815 | 3.5 K to 4.8 K (+39.36 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Lloyd Marcea Bland | SVP Gov Corp Affa ... | Grant | A | 17.83 | 412 | 7,346 | 3,490 | 3.1 K to 3.5 K (+13.39 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Marshall Paul | SVP Operations | Option Exercise | A | 18.01 | 63,096 | 1,136,359 | 63,096 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Marshall Paul | SVP Operations | Option Exercise | A | 18.01 | 6,904 | 124,341 | 6,904 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Marshall Paul | SVP Operations | Grant | A | 0.00 | 1,360 | 0 | 4,815 | 3.5 K to 4.8 K (+39.36 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Marshall Paul | SVP Operations | Grant | A | 17.83 | 412 | 7,346 | 1,179 | 767 to 1.2 K (+53.72 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP Corporate Deve ... | Option Exercise | A | 18.01 | 63,252 | 1,139,169 | 63,252 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP Corporate Deve ... | Option Exercise | A | 18.01 | 6,748 | 121,531 | 6,748 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP Corporate Deve ... | Grant | A | 0.00 | 1,360 | 0 | 4,815 | 3.5 K to 4.8 K (+39.36 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP Corporate Deve ... | Grant | A | 17.83 | 412 | 7,346 | 6,079 | 5.7 K to 6.1 K (+7.27 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | A | 18.01 | 244,448 | 4,402,508 | 244,448 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | A | 18.01 | 5,552 | 99,992 | 5,552 | |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Grant | A | 0.00 | 1,360 | 0 | 4,815 | 3.5 K to 4.8 K (+39.36 %) |
| Feb 04 2010 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Grant | A | 17.83 | 412 | 7,346 | 16,524 | 16.1 K to 16.5 K (+2.56 %) |
| Jan 12 2010 | AMLN | AMYLIN PHARMACEUTI ... | SULLIVAN JOSEPH P | Director | Option Exercise | A | 0.00 | 1,096 | 0 | 14,462 | |
| Jan 12 2010 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Option Exercise | A | 0.00 | 576 | 0 | 9,064 | |
| Jan 12 2010 | AMLN | AMYLIN PHARMACEUTI ... | CLARK PAUL N | Director | Option Exercise | A | 0.00 | 928 | 0 | 2,997 | |
| Jan 12 2010 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Option Exercise | A | 0.00 | 1,211 | 0 | 10,586 | |
| Jan 12 2010 | AMLN | AMYLIN PHARMACEUTI ... | ALTMAN STEVEN R | Director | Option Exercise | A | 0.00 | 928 | 0 | 9,273 | |
| Oct 06 2009 | AMLN | AMYLIN PHARMACEUTI ... | SULLIVAN JOSEPH P | Director | Option Exercise | A | 0.00 | 1,292 | 0 | 13,366 | |
| Oct 06 2009 | AMLN | AMYLIN PHARMACEUTI ... | CLARK PAUL N | Director | Option Exercise | A | 0.00 | 1,101 | 0 | 2,069 | |
| Oct 06 2009 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Option Exercise | A | 0.00 | 1,435 | 0 | 9,375 | |
| Oct 06 2009 | AMLN | AMYLIN PHARMACEUTI ... | ALTMAN STEVEN R | Director | Option Exercise | A | 0.00 | 1,101 | 0 | 8,345 | |
| Oct 06 2009 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Option Exercise | A | 0.00 | 904 | 0 | 8,488 | |
| Oct 06 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTHAM KARIN | Director | Option Exercise | A | 0.00 | 1,627 | 0 | 15,244 | |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 13.89 | 428,574 | 5,953,750 | 13,346,120 | 13.8 M to 13.3 M (-3.11 %) |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 13.93 | 180,000 | 2,506,806 | 13,774,694 | 14 M to 13.8 M (-1.29 %) |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 13.96 | 475,000 | 6,631,238 | 13,954,694 | 14.4 M to 14 M (-3.29 %) |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 13.99 | 305,711 | 4,277,478 | 14,429,694 | 14.7 M to 14.4 M (-2.07 %) |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 13.98 | 3,100 | 43,323 | 14,735,405 | 14.7 M to 14.7 M (-0.02 %) |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 13.98 | 22,500 | 314,550 | 14,738,505 | 14.8 M to 14.7 M (-0.15 %) |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 14.01 | 28,356 | 397,228 | 14,761,005 | 14.8 M to 14.8 M (-0.19 %) |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 14.09 | 300,000 | 4,225,500 | 14,789,361 | 15.1 M to 14.8 M (-1.99 %) |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 14.12 | 62,200 | 878,519 | 15,089,361 | 15.2 M to 15.1 M (-0.41 %) |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 14.15 | 284,900 | 4,032,133 | 15,151,561 | 15.4 M to 15.2 M (-1.85 %) |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 14.11 | 483,402 | 6,822,107 | 15,436,461 | 15.9 M to 15.4 M (-3.04 %) |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 14.31 | 17,437 | 249,525 | 15,919,863 | 15.9 M to 15.9 M (-0.11 %) |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 14.13 | 796,400 | 11,252,017 | 15,937,300 | 16.7 M to 15.9 M (-4.76 %) |
| Sep 18 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTBOURNE CAPITAL MANAGEMENT ... | 10% Owner | Sell | S | 14.22 | 466,300 | 6,628,688 | 16,733,700 | 17.2 M to 16.7 M (-2.71 %) |
| Jul 09 2009 | AMLN | AMYLIN PHARMACEUTI ... | SULLIVAN JOSEPH P | Director | Option Exercise | A | 0.00 | 1,452 | 0 | 12,074 | |
| Jul 09 2009 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Option Exercise | A | 0.00 | 813 | 0 | 7,584 | |
| Jul 09 2009 | AMLN | AMYLIN PHARMACEUTI ... | EASTHAM KARIN | Director | Option Exercise | A | 0.00 | 1,646 | 0 | 13,617 | |
| Jul 09 2009 | AMLN | AMYLIN PHARMACEUTI ... | CLARK PAUL N | Director | Option Exercise | A | 0.00 | 968 | 0 | 968 | |
| Jul 09 2009 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Option Exercise | A | 0.00 | 1,259 | 0 | 7,940 | |
| Jul 09 2009 | AMLN | AMYLIN PHARMACEUTI ... | ALTMAN STEVEN R | Director | Option Exercise | A | 0.00 | 968 | 0 | 7,244 | |
| Jun 11 2009 | AMLN | AMYLIN PHARMACEUTI ... | ADAMS ADRIAN | Director | Option Exercise | A | 11.68 | 20,000 | 233,600 | 20,000 |